CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Apalutamide (Erleada) for Metastatic Castration-Sensitive Prostate Cancer - Details

Project Number PC0200-000
Brand Name Erleada
Generic Name Apalutamide
Strength 60 mg
Tumour Type Genitourinary
Indication Metastatic Castration-Sensitive Prostate Cancer
Funding Request For the treatment of metastatic castration-sensitive prostate cancer (mCSPC)
Review Status Complete
Pre Noc Submission Yes
NOC Date December 12, 2019
Manufacturer Janssen Inc.
Sponsor Janssen Inc.
Submission Date October 15, 2019
Submission Deemed Complete October 29, 2019
Submission Type Initial
Prioritization Requested
Stakeholder Input Deadline ‡ October 29, 2019
Check-point meeting December 17, 2019
pERC Meeting March 19, 2020
Initial Recommendation Issued April 2, 2020
Feedback Deadline ‡ April 17, 2020
Final Recommendation Issued April 22, 2020
Notification to Implement Issued May 7, 2020
Therapeutic Area metastatic castration-sensitive prostate cancer (mCSPC)
Recommendation Type Reimburse with clinical criteria and/or conditions

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.